Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL adoptive cell therapy with chemotherapy with or without interferon alfa in recurrent ovarian cancer
NL-OMON46501Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of GC101 TIL + pembrolizumab, interferon alfa, carboplatin and paclitaxel in epithelial ovarian cancer (EOC) (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoint: TIL (plus interferon alfa) related toxicity. Started Nov 2018; status: completed.
02
Drugs
GC101 TIL + pembrolizumabinterferon alfacarboplatinpaclitaxel
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NL-OMON46501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46501.